225 related articles for article (PubMed ID: 25181310)
1. Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans.
Blanco I; Mathai S; Shafiq M; Boyce D; M Kolb T; Chami H; K Hummers L; Housten T; Chaisson N; L Zaiman A; M Wigley F; J Tedford R; A Kass D; Damico R; E Girgis R; M Hassoun P
Medicine (Baltimore); 2014 Jul; 93(5):177-185. PubMed ID: 25181310
[TBL] [Abstract][Full Text] [Related]
2. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
[TBL] [Abstract][Full Text] [Related]
3. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
4. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
[TBL] [Abstract][Full Text] [Related]
5. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
[TBL] [Abstract][Full Text] [Related]
6. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
[TBL] [Abstract][Full Text] [Related]
7. Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension.
Tedford RJ; Mudd JO; Girgis RE; Mathai SC; Zaiman AL; Housten-Harris T; Boyce D; Kelemen BW; Bacher AC; Shah AA; Hummers LK; Wigley FM; Russell SD; Saggar R; Saggar R; Maughan WL; Hassoun PM; Kass DA
Circ Heart Fail; 2013 Sep; 6(5):953-63. PubMed ID: 23797369
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis.
Ciurzyński M; Bienias P; Lichodziejewska B; Kurnicka K; Szewczyk A; Glińska-Wielochowska M; Kurzyna M; Błaszczyk M; Liszewska-Pfejfer D; Pruszczyk P
Clin Rheumatol; 2008 Aug; 27(8):991-7. PubMed ID: 18256871
[TBL] [Abstract][Full Text] [Related]
9. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
[TBL] [Abstract][Full Text] [Related]
10. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension.
Takatsuki S; Wagner BD; Ivy DD
Congenit Heart Dis; 2012; 7(3):259-67. PubMed ID: 22325151
[TBL] [Abstract][Full Text] [Related]
11. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
[TBL] [Abstract][Full Text] [Related]
12. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.
Thakkar V; Stevens W; Prior D; Youssef P; Liew D; Gabbay E; Roddy J; Walker JG; Zochling J; Sahhar J; Nash P; Lester S; Rischmueller M; Proudman SM; Nikpour M
Arthritis Res Ther; 2013; 15(6):R193. PubMed ID: 24246100
[TBL] [Abstract][Full Text] [Related]
13. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension.
Mathai SC; Sibley CT; Forfia PR; Mudd JO; Fisher MR; Tedford RJ; Lechtzin N; Boyce D; Hummers LK; Housten T; Zaiman AL; Girgis RE; Hassoun PM
J Rheumatol; 2011 Nov; 38(11):2410-8. PubMed ID: 21965638
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of exercise pulmonary arterial hypertension in scleroderma.
Callejas-Rubio JL; Moreno-Escobar E; de la Fuente PM; Pérez LL; Fernández RR; Sánchez-Cano D; Mora JP; Ortego-Centeno N
J Rheumatol; 2008 Sep; 35(9):1812-6. PubMed ID: 18634147
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical importance of gastroesophageal reflux in Chinese patients with systemic sclerosis.
Liu X; Li M; Xu D; Hou Y; Wang Q; Tian Z; Sun Q; Zeng X
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S60-6. PubMed ID: 22691211
[TBL] [Abstract][Full Text] [Related]
17. [The clinical characteristics of systemic sclerosis-related pulmonary arterial hypertension].
Wang H; Tian Z; Liu Y; Li M; Wang Q; Zeng X; Fang Q
Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):390-3. PubMed ID: 25146407
[TBL] [Abstract][Full Text] [Related]
18. Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma.
Kiatchoosakun S; Wongvipaporn C; Nanagara R; Hoit BD
Clin Cardiol; 2011 Aug; 34(8):488-93. PubMed ID: 21717471
[TBL] [Abstract][Full Text] [Related]
19. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.
Mathai SC; Bueso M; Hummers LK; Boyce D; Lechtzin N; Le Pavec J; Campo A; Champion HC; Housten T; Forfia PR; Zaiman AL; Wigley FM; Girgis RE; Hassoun PM
Eur Respir J; 2010 Jan; 35(1):95-104. PubMed ID: 19643943
[TBL] [Abstract][Full Text] [Related]
20. Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se.
Lindholm A; Hesselstrand R; Rådegran G; Arheden H; Ostenfeld E
Clin Physiol Funct Imaging; 2019 May; 39(3):215-225. PubMed ID: 30597705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
